Biovica International AB (publ)
The answer first
Does Biovica International beat the market?
No, Biovica International has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 17% of Nordic stocks
- Quality69
- Value14
- Trend17
No. 137 of 195 in healthcare
Max for seven days
Follow Biovica International with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 20 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Biovica International
Your first answer is free, no account needed.
Do you own Biovica International, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Biovica International and a few more. Free, no card.
Super Stock+45.3%In short
- Biovica International has fallen 43.8% over the past year, including dividends.
- Overall, Biovica International ranks better than 17% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 98.3%. The price is 99.5% below its peak now.
What do analysts think of Biovica International?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 17% of Nordic stocks.
No. 137 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 87 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.17
- Asset turnoverSales divided by everything the company owns0.16
- Return on equityProfit divided by equity−108.5%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 121 of 197 in healthcareTypical in healthcare: 19Typical in the Nordics: 50
- P/BPrice divided by equity1.3
- P/SPrice divided by sales5.8
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 134 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−33.3%
- 6 months−8.8%
- 9 months−18.9%
- 12 months−43.8%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Biovica International
One fund we follow owns Biovica International. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Biovica International
Biovica International AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. By market value, Biovica International is number 91 of 137 companies in healthcare on Nasdaq Stockholm. Biovica International has not paid a dividend in the past twelve months. Of the three measures in the ranking, Biovica International is strongest on quality, better than 69% of Nordic stocks. The share trades in SEK. It has around 24 employees.
Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia. The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors. It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.


See the full analysis of Biovica International.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card